Evogliptin Completed Phase 4 Trials for Type 2 Diabetes Mellitus / Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT03910361Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases